Corindus Vascular Robotics Inc (NYSEMKT:CVRS) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Several other research firms have also recently weighed in on CVRS. Zacks Investment Research raised Corindus Vascular Robotics from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research note on Tuesday, August 29th. ValuEngine lowered Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a report on Monday, July 17th. Finally, Cowen and Company set a $3.00 price target on Corindus Vascular Robotics and gave the company a “buy” rating in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Corindus Vascular Robotics currently has an average rating of “Hold” and a consensus price target of $2.67.

Corindus Vascular Robotics (NYSEMKT:CVRS) traded down 0.61% on Friday, reaching $1.62. 384,040 shares of the company traded hands. The firm has a 50 day moving average price of $1.70 and a 200 day moving average price of $1.42. The stock’s market capitalization is $303.42 million. Corindus Vascular Robotics has a 52-week low of $0.40 and a 52-week high of $2.25.

Corindus Vascular Robotics (NYSEMKT:CVRS) last released its earnings results on Tuesday, August 8th. The medical equipment provider reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Corindus Vascular Robotics had a negative return on equity of 94.27% and a negative net margin of 372.63%. The company had revenue of $2.26 million for the quarter, compared to analysts’ expectations of $3.10 million. Equities research analysts predict that Corindus Vascular Robotics will post ($0.21) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/08/corindus-vascular-robotics-inc-cvrs-stock-rating-lowered-by-bidaskclub.html.

Several institutional investors have recently made changes to their positions in CVRS. Bank of New York Mellon Corp lifted its holdings in shares of Corindus Vascular Robotics by 6.3% during the 1st quarter. Bank of New York Mellon Corp now owns 163,012 shares of the medical equipment provider’s stock valued at $214,000 after buying an additional 9,684 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Corindus Vascular Robotics by 73.3% during the 1st quarter. Geode Capital Management LLC now owns 673,488 shares of the medical equipment provider’s stock valued at $882,000 after buying an additional 284,855 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Corindus Vascular Robotics by 240.4% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 285,900 shares of the medical equipment provider’s stock valued at $375,000 after buying an additional 201,900 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Corindus Vascular Robotics by 67.6% during the 2nd quarter. Rhumbline Advisers now owns 80,868 shares of the medical equipment provider’s stock valued at $150,000 after buying an additional 32,608 shares during the last quarter. Finally, Teachers Advisors LLC lifted its holdings in shares of Corindus Vascular Robotics by 184.7% during the 2nd quarter. Teachers Advisors LLC now owns 167,633 shares of the medical equipment provider’s stock valued at $312,000 after buying an additional 108,745 shares during the last quarter.

Corindus Vascular Robotics Company Profile

Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.

Receive News & Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related companies with MarketBeat.com's FREE daily email newsletter.